Justin Petrone

Mursla Bio, a Cambridge, UK-based company that focuses on EV isolation, biomarker discovery from EV cargo, and EV assays for clinical use, is an EVEREST participant.

The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.

The Swedish single-cell RNA-sequencing startup plans to bring new applications to its services menu as a partnership with MGI begins to yield kitted products.

While the researchers have no plans to sell RNA chips based on the technology, they do intend to commercialize a device for synthesizing high-density arrays.

GMS will also use the funding for studies related to childhood cancer and rare diseases and to continue the development of a National Genomics Platform.

The biobank will use the genome sequencing data to inform various personalized medicine projects focused on cardiovascular disease, pharmacogenomics, cancer, and rare diseases.

A new project called Genome of Europe, to be funded by the European Commission, plans to generate 500,000 genomes from 40 European populations.

The UK firm has found an early partner in Public Health Wales, which will soon begin validating the platform.

The company is also preparing to raise a Series A financing round to establish its technology in other application areas.

The researchers found that whole-genome sequencing yielded more comprehensive information than relying on cancer panels.